Vaxil BioTherapeutics made its debut on the Tel Aviv Stock Exchange through a merger with Sheldonco. Sheldonco acquired Vaxil in full, according to a release, giving Vaxil shareholders 56% stake in Sheldonco on a fully diluted basis. The holding will shoot up to 74% in Sheldonco if the developer of cancer and infectious disease vaccines hits two research milestones. Release | Story (sub. req.)